Urinary Tract Infection Testing Market was valued at USD 625.23 million in 2023 and is expected to reach USD 1004.64 million by 2032, growing at a CAGR of 5.45% from 2024-2032.
The Urinary Tract Infection (UTI) Testing Market report offers insights into key statistical factors, such as the prevalence and incidence of UTIs within various regions, to highlight demographic differences. The report also discusses testing volume trends, with a focus on the move away from traditional culture-based technologies towards rapid diagnostic solutions. The report is also a step into prescription tendencies, outlining frequently prescribed antibiotics as well as treatment effectiveness affected by antimicrobial resistance. The adoption of rapid tests for UTIs is also given attention, discussing technological innovations. Finally, healthcare expenditure breakdown on UTI diagnostic and treatment in terms of government, commercial, private, and out-of-pocket spending is also provided.
The United States holds the dominating CAGR of 5.84% in the urinary tract infection (UTI) testing market in North America with its superior healthcare infrastructure and high diagnostic rate. The nation experiences a high prevalence of UTIs with more than 10 million healthcare visits every year caused by UTIs. Moreover, the high usage of rapid diagnostic tests and growing antimicrobial resistance fuel the need for superior UTI testing solutions. Government programs and health spending also reinforce the U.S.'s top position in the market.
Drivers
A growing number of urinary tract infections (UTIs) all over the world is one of the major forces for the market of UTI testing.
According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), UTIs make up close to 10 million healthcare visits a year in the United States alone, with more risk in females owing to their anatomical setup. Also, the World Health Organization (WHO) cites antimicrobial resistance (AMR) as a burgeoning issue requiring more accurate and speedy diagnostic platforms. Recent progress in UTI diagnostics, e.g., Quidel Corporation's rapid UTI test available since June 2024, facilitates faster identification of bacteria and antibiotic susceptibility tests in 45 minutes, bettering treatment guidelines. The increasing occurrence of repeat UTIs and growing demands for prompt identification equipment remain a strong force propelling the business of cutting-edge test kits.
Technology Evolution in Urinalysis and Molecular Diagnostic Techniques propelling the market growth.
The market for UTI testing is also enjoying rapid technological innovation in diagnostic techniques, providing greater accuracy, speed, and convenience. Conventional culture testing is increasingly being superseded by automated urinalysis systems and molecular testing, which provide quicker and more accurate results. In December 2023, Siemens Healthineers launched the Atellica UAS 60 Analyzer, which is an automated urine sediment analytical system that contributes to laboratory productivity with digital image analysis, mitigating the need for manual microscopy. Furthermore, PCR-based examinations and AI-aided diagnostics are becoming more popular, permitting quick identification of certain bacterial types and antibiotic resistance determinants. The integration of such advanced technologies in UTI diagnostics provides early disease diagnosis and personalized treatment strategies, hence driving the market.
Restraint
One of the major constraints in the urinary tract infection (UTI) testing market is the high expense of sophisticated diagnostic techniques and their limited availability in low-resource environments.
Conventional urine culture tests are relatively inexpensive but result in a delay of 24 to 48 hours, hindering treatment decisions. By comparison, newer molecular testing technologies like automated urinalysis analyzers and PCR-based diagnostics are faster, and more accurate but much more costly. For example, molecular-technology-based UTI rapid testing can be as much as 5–10 times more expensive than traditional systems, thus proving to be an unaffordable option for people in developing parts of the world. The prerequisite for sophisticated lab facilities and specially trained staff further restricts adoption in resource-poor or rural and developing regions. This barrier to cost inhibits the extensive adoption of advanced diagnostic solutions, hindering market penetration in cost-sensitive markets.
Opportunities
Increasing pressure for fast, affordable, and convenient UTI testing represents a significant opportunity for growth in point-of-care (POC) testing solutions.
Standard urine culture testing, up to 48 hours, too often postpones treatment decisions, allowing continued discomfort and complications. Point-of-care diagnostic instruments, like automated dipstick analyzers and molecular-based quick UTI tests, allow direct infection detection in minutes. Players such as Siemens Healthineers and Quidel Corporation are making investments in handheld UTI diagnostic systems reducing dependence on core labs. A rise in the use of telemedicine also accompanies the opportunity as self-test kits delivered at the door provide patient tracking from home. As infections of antibiotic-resistant form gain strength the world over, instant POC testing for inclusion of antimicrobial susceptibility evaluation will additionally help market growth to support more optimized treatment options.
Challenges
One of the primary challenges in the UTI test market is rising antimicrobial resistance (AMR), which challenges the efficacy and accuracy of existing testing methods.
Conventional diagnostics based on urine culture depend upon the detection of bacterial growth, but with evolving resistant strains, conventional treatments fall short, promoting recurrent infections as well as inaccurate diagnoses. More than 30% of E. coli UTIs worldwide are resistant to first-line antibiotics, complicating standard testing's ability to predict treatment. False negatives and inconclusive findings further complicate effective diagnosis, necessitating more advanced molecular tests that increase cost and complexity. As AMR increases, the demand for next-generation diagnostic tools with real-time resistance profiling is urgent, but widespread implementation remains a challenge due to infrastructure and affordability constraints.
By Type
The Cystitis segment dominated the urinary tract infection testing market with a 43.25% market share in 2023 based mainly on its high frequency and recurring nature in individuals, particularly women. Clinically, it has been estimated that almost 50–60% of women have at least one occurrence of cystitis in their lifetime, with recurrent infection being common. The growing application of point-of-care (POC) tests, dipstick urinalysis, and urine culture testing drove market demand for cystitis diagnosis. Furthermore, market pressures such as increasing antibiotic resistance, dehydration, and catheter-associated infections among patients admitted to hospitals have increased the frequency of screenings. The extensive availability of quick-testing solutions, combined with rising awareness and early detection efforts, has also strengthened the market leadership of the cystitis segment.
The Pyelonephritis segment is experience to grow at the fastest rate during the forecast period with a 6.25% CAGR, influenced by growing numbers of complicated UTIs, antibiotic resistance, and better awareness about infections in kidneys. Pyelonephritis is a serious kidney infection that usually arises because of untreated or inadequately treated lower urinary tract infections (like cystitis). Based on health reports, inpatient admissions due to pyelonephritis have increased significantly, and subsequently, there has been a greater need for sophisticated laboratory tests such as urine culture, blood work, and imaging modalities. Increasing use of molecular diagnostic technologies and quick AST is improving early detection and treatment decisions. Moreover, the increasing aging population, increasing incidence of diabetes, and escalating healthcare spending in emerging economies are also propelling the segment's speedy growth in the UTI testing market.
By End Use
The Reference Laboratories segment dominated the urinary tract infection testing market with a 27.10% market share in 2023, mainly because of their high testing capacity, sophisticated diagnostic technologies, and wide service networks. These labs provide thorough urine culture tests, antimicrobial susceptibility testing (AST), and molecular diagnostics, providing precise and detailed results for UTI diagnosis. With growing antibiotic resistance, doctors and hospitals increasingly turn to reference labs for accurate identification of pathogens and targeted treatment protocols. The increasing trend among hospitals, clinics, and primary care physicians to prefer outsourced laboratory testing has further driven the segment's dominance. The presence of automated urine analyzers, PCR-based diagnostic tests, and AI-enabled laboratory workflows has boosted the position of reference labs in delivering quicker, more accurate, and high-throughput UTI testing solutions.
The Urogynecologists segment is anticipated to experience the fastest growth in the next forecast years on the back of rising awareness regarding repeat UTIs, growing cases of pelvic floor disorders, and the aging population. Specialists in urogynecology are trained to provide treatment for complex urinary tract infections, incontinence, and bladder dysfunction and therefore become instrumental in advanced UTI diagnosis and treatment planning. The growing incidence of recurrent UTIs in postmenopausal women, infections in pregnancy, and catheter-associated UTIs in the elderly has created a greater need for special diagnostics. Moreover, advancements in technology like non-invasive diagnostic devices, real-time PCR diagnostics, and point-of-care urine analysis are empowering urogynecologists to offer speedier and more customized care. With increased patient referrals, better diagnostic tools, and increased demand for specialized procedures, this segment is likely to witness significant growth over the forecast period.
North America dominated the urinary tract infection (UTI) testing market with a 35.42% market share in 2023, mainly because of its sophisticated healthcare infrastructure, high level of awareness, and robust presence of major market players like Abbott, Becton Dickinson, and Siemens Healthineers. The growing incidence of UTIs, especially among women, the elderly, and diabetic patients, has created a high demand for rapid and precise diagnostic tools. As per the CDC, UTIs contribute to approximately 8 million healthcare visits each year in the U.S., making it a key area for diagnostic innovation. Moreover, favorable reimbursement policies, high usage of point-of-care (POC) diagnostic technologies, and government support for early disease detection also add to market leadership.
The Asia Pacific region is experiencing the fastest growth with a 6.65% CAGR in the UTI test market throughout the forecast period, fueled by high infection rates, expanding healthcare access, and an expanding geriatric population. China, India, and Japan are among the countries seeing a high increase in UTI cases, mostly attributed to inadequate sanitation, growing antibiotic resistance, and inadequate early diagnosis in rural populations. Based on the WHO, UTI cases due to antimicrobial resistance are increasing exponentially in Southeast Asia, which calls for more sophisticated diagnostic solutions. The growth of telehealth, government healthcare initiatives, and private investment in diagnostic centers is driving market penetration at a faster pace. Moreover, rising awareness, cost-effective diagnostics, and the presence of new entrants working on cost-efficient solutions are making Asia Pacific the most rapidly growing UTI testing market.
Abbott Laboratories (Uristat Relief Pak, UTI Test Strips)
Siemens Healthineers (CLINITEK Status+ Analyzer, Multistix 10 SG Reagent Strips)
Becton, Dickinson and Company (BD) (BD UTI ESwab Collection Kit, BD Phoenix M50 Automated Microbiology System)
bioMérieux SA (VITEK 2 Compact System, ChromID CPS Elite Agar)
Thermo Fisher Scientific Inc. (Sensititre ARIS 2X System, Remel Spectra UTI Agar)
Quidel Corporation (QuickVue UTI Test, Sofia 2 Fluorescent Immunoassay Analyzer)
Roche Diagnostics (Urisys 1100 Urine Analyzer, Combur-Test Strips)
Danaher Corporation (DxC 700 AU Chemistry Analyzer, KOVA-Trol Urinalysis Quality Control)
Hologic, Inc. (Aptima Urine Specimen Collection Kit, Panther System)
ACON Laboratories, Inc. (Mission UTI Urinalysis Reagent Strips, HealthyMe UTI Test)
Sekisui Diagnostics (Solaris UTI Test, OSOM UTI Test)
Bio-Rad Laboratories, Inc. (Uri-Trak 120 Urine Analyzer, Liquichek Urinalysis Control)
Cardinal Health (SureStep Urine Reagent Strips, CONSULT Urinalysis Analyzer)
Arkray, Inc. (AUCTION MAX AX-4030 Urine Analyzer, AUTION Sticks 10PA)
Siemens Healthineers (Atellica 1500 Automated Urinalysis System, CLINITEK Advantus Urine Chemistry Analyzer)
Beckman Coulter, Inc. (IRICELL Series Urinalysis Workcell, iRICELL3000 Automated Urinalysis System)
Sysmex Corporation (UF-5000 Fully Automated Urine Particle Analyzer, UN-Series Urinalysis Solution)
Meridian Bioscience, Inc. (ImmunoCard STAT! E. coli O157 Plus, TRU Legionella)
OraSure Technologies, Inc. (Intercept Oral Fluid Drug Test, Q.E.D. Saliva Alcohol Test)
Alere Inc. (Alere iCup Drug Screen, Alere Triage TOX Drug Screen)
Suppliers (These suppliers provide diagnostic reagents, laboratory instruments, and consumables essential for accurate urinary tract infection (UTI) testing, supporting clinical laboratories, hospitals, and point-of-care testing centers.) In Urinary Tract Infection Testing Market
Merck KGaA
Thermo Fisher Scientific Inc.
Sigma-Aldrich Corporation
Beckman Coulter, Inc.
BD (Becton, Dickinson, and Company)
Roche Diagnostics
Siemens Healthineers
Bio-Rad Laboratories, Inc.
PerkinElmer, Inc.
Agilent Technologies, Inc.
June 2024 – Quidel Corporation has launched a new, state-of-the-art rapid test for urinary tract infections (UTIs), the test being capable of identifying the causative bacteria and performing antibiotic susceptibility testing (AST) in only 45 minutes. The new test employs a single-use cartridge, boosting the efficiency and accuracy of UTI diagnosis.
December 2023 – Siemens Healthineers introduced the Atellica UAS 60 Analyzer, a small urine sediment analysis system that automates laboratory urinalysis processes. Through the use of full field-of-view digital imaging, the analyzer mimics manual microscopy, allowing laboratory staff to obtain quicker and more precise urine sediment analysis with less dependence on conventional manual procedures.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 625.23 million |
| Market Size by 2032 | US$ 1004.64 million |
| CAGR | CAGR of 5.45% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Urethritis, Cystitis, Pyelonephritis) • By End Use (General Practitioners (GPs), Urologists, Urogynecologists, Hospital Laboratories, Reference Laboratories, Hospital Emergency Departments, Urgent Care, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Abbott Laboratories, Siemens Healthineers, Becton, Dickinson and Company (BD), bioMérieux SA, Thermo Fisher Scientific Inc., Quidel Corporation, Roche Diagnostics, Danaher Corporation, Hologic, Inc., ACON Laboratories, Inc., Sekisui Diagnostics, Bio-Rad Laboratories, Inc., Cardinal Health, Arkray, Inc., Beckman Coulter, Inc., Sysmex Corporation, Meridian Bioscience, Inc., OraSure Technologies, Inc., Alere Inc., and other players. |
Ans: The Urinary Tract Infection Testing Market is expected to grow at a CAGR of 5.45% during 2024-2032.
Ans: The Urinary Tract Infection Testing Market was USD 625.23 million in 2023 and is expected to Reach USD 1004.64 million by 2032.
Ans: Technology Evolution in Urinalysis and Molecular Diagnostic Techniques propelling the market growth.
Ans: The “Cystitis” segment dominated the Urinary Tract Infection Testing Market.
Ans: North America dominated the Urinary Tract Infection Testing Market in 2023.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of UTIs (2023, by Region)
5.2 UTI Testing Volume Trends (2020-2032, by Region)
5.3 Prescription Trends for UTI Treatment (2023, by Region)
5.4 Adoption of Rapid UTI Testing Methods (2020-2032)
5.5 Healthcare Spending on UTI Diagnostics and Treatment (2023, by Payer Type – Government, Commercial, Private, Out-of-Pocket)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Urinary Tract Infection Testing Market Segmentation, By Type
7.1 Chapter Overview
7.2 Urethritis
7.2.1 Urethritis Market Trends Analysis (2020-2032)
7.2.2 Urethritis Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Cystitis
7.3.1 Cystitis Market Trends Analysis (2020-2032)
7.3.2 Cystitis Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 Pyelonephritis
7.4.1 Pyelonephritis Market Trends Analysis (2020-2032)
7.4.2 Pyelonephritis Market Size Estimates and Forecasts to 2032 (USD Million)
8. Urinary Tract Infection Testing Market Segmentation, by End Use
8.1 Chapter Overview
8.2 General Practitioners (GPs)
8.2.1 General Practitioners (GPs) Market Trends Analysis (2020-2032)
8.2.2 General Practitioners (GPs) Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Urologists
8.3.1 Urologists Market Trends Analysis (2020-2032)
8.3.2 Urologists Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Urogynecologists
8.4.1 Urogynecologists Market Trends Analysis (2020-2032)
8.4.2 Urogynecologists Market Size Estimates and Forecasts to 2032 (USD Million)
8.5 Hospital Laboratories
8.5.1 Hospital Laboratories Market Trends Analysis (2020-2032)
8.5.2 Hospital Laboratories Market Size Estimates and Forecasts to 2032 (USD Million)
8.6 Reference Laboratories
8.6.1 Reference Laboratories Market Trends Analysis (2020-2032)
8.6.2 Reference Laboratories Market Size Estimates and Forecasts to 2032 (USD Million)
8.7 Hospital Emergency Departments
8.7.1 Hospital Emergency Departments Market Trends Analysis (2020-2032)
8.7.2 Hospital Emergency Departments Market Size Estimates and Forecasts to 2032 (USD Million)
8.8 Urgent Care
8.8.1 Urgent Care Market Trends Analysis (2020-2032)
8.8.2 Urgent Care Market Size Estimates and Forecasts to 2032 (USD Million)
8.9 Others
8.9.1 Others Market Trends Analysis (2020-2032)
8.9.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Urinary Tract Infection Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.2.3 North America Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.2.4 North America Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.2.5 USA
9.2.5.1 USA Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.2.5.2 USA Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.2.6 Canada
9.2.6.1 Canada Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.2.6.2 Canada Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.2.7 Mexico
9.2.7.1 Mexico Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.2.7.2 Mexico Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Urinary Tract Infection Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.3.1.3 Eastern Europe Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.1.4 Eastern Europe Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.1.5 Poland
9.3.1.5.1 Poland Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.1.5.2 Poland Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.1.6 Romania
9.3.1.6.1 Romania Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.1.6.2 Romania Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.1.7.2 Hungary Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.1.8.2 Turkey Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.1.9.2 Rest of Eastern Europe Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Urinary Tract Infection Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.3.2.3 Western Europe Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.4 Western Europe Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.5 Germany
9.3.2.5.1 Germany Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.5.2 Germany Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.6 France
9.3.2.6.1 France Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.6.2 France Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.7 UK
9.3.2.7.1 UK Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.7.2 UK Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.8 Italy
9.3.2.8.1 Italy Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.8.2 Italy Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.9 Spain
9.3.2.9.1 Spain Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.9.2 Spain Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.10.2 Netherlands Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.11.2 Switzerland Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.12 Austria
9.3.2.12.1 Austria Healthcare Predictive Analytic Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.12.2 Austria Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.13.2 Rest of Western Europe Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Urinary Tract Infection Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.4.3 Asia Pacific Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.4 Asia Pacific Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.5 China
9.4.5.1 China Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.5.2 China Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.6 India
9.4.5.1 India Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.5.2 India Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.5 Japan
9.4.5.1 Japan Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.5.2 Japan Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.6 South Korea
9.4.6.1 South Korea Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.6.2 South Korea Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.7 Vietnam
9.4.7.1 Vietnam Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.2.7.2 Vietnam Healthcare Predictive Analytic Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.8 Singapore
9.4.8.1 Singapore Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.8.2 Singapore Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.9 Australia
9.4.9.1 Australia Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.9.2 Australia Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.10.2 Rest of Asia Pacific Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Urinary Tract Infection Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.5.1.3 Middle East Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.1.4 Middle East Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.1.5 UAE
9.5.1.5.1 UAE Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.1.5.2 UAE Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.1.6.2 Egypt Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.1.7.2 Saudi Arabia Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.1.8.2 Qatar Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.1.9.2 Rest of Middle East Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Urinary Tract Infection Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.5.2.3 Africa Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.2.4 Africa Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.2.5.2 South Africa Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.2.6.2 Nigeria Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.2.7 Rest of Africa
9.5.2.7.1 Rest of Africa Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.2.7.2 Rest of Africa Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Urinary Tract Infection Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.6.3 Latin America Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.6.4 Latin America Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.6.5 Brazil
9.6.5.1 Brazil Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.6.5.2 Brazil Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.6.6 Argentina
9.6.6.1 Argentina Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.6.6.2 Argentina Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.6.7 Colombia
9.6.7.1 Colombia Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.6.7.2 Colombia Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Urinary Tract Infection Testing Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.6.8.2 Rest of Latin America Urinary Tract Infection Testing Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10. Company Profiles
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 Siemens Healthineers
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 Becton, Dickinson and Company
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 bioMérieux SA
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Thermo Fisher Scientific Inc.
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 Quidel Corporation
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Roche Diagnostics
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Danaher Corporation
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Hologic, Inc.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 ACON Laboratories, Inc.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Urinary Tract Infection Testing Market Key Segments:
By Type
Urethritis
Cystitis
Pyelonephritis
By End Use
General Practitioners (GPs)
Urologists
Urogynecologists
Hospital Laboratories
Reference Laboratories
Hospital Emergency Departments
Urgent Care
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Conjunctivitis Treatment Market size was USD 4.2 Billion in 2023 and is expected to Reach USD 6.3 Billion by 2032 and grow at a CAGR of 4.7% over the forecast period of 2024-2032.
The Cone Beam Computer Tomography (CBCT) Market Size was valued at USD 541.93 million in 2023, and is expected to reach USD 1342.77 million by 2031, and grow at a CAGR of 12.01% over the forecast period 2024-2031.
The Bio Decontamination Market was valued at USD 236.09 million in 2023 and is expected to reach USD 501.37 million by 2032, growing at a CAGR of 8.76% from 2024-2032.
The AI in Medical Imaging Market size was valued at USD 1.76 billion in 2023 and is projected to reach USD 23.65 billion by 2032, growing at a 33.48% CAGR.
The Drug Eluting Stent Market size was estimated at USD 7.80 Billion in 2023 and is expected to reach USD 14.98 Billion by 2031 at a CAGR of 8.5% during the forecast period of 2024-2031.
The Biochips Market was valued at USD 10.35 billion in 2023 and is expected to reach USD 35.00 billion by 2032, growing at a CAGR of 14.52% from 2024 to 2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
